Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition—A Prospective Multicenter Study DOI Creative Commons
Andreas Blesl, Philipp Wurm, Silvio Waschina

et al.

Inflammatory Bowel Diseases, Journal Year: 2023, Volume and Issue: 30(1), P. 9 - 19

Published: July 18, 2023

Abstract Background Corticosteroids are used for induction of remission in patients with moderately to severely active ulcerative colitis. However, up one-third fail this therapy. We investigated if fecal microbial composition or its metabolic capacity associated response systemic corticosteroids. Methods In prospective, multicenter study, colitis (Lichtiger score ≥4) receiving corticosteroids were eligible. Data assessed and samples collected before after 4 weeks treatment. Patients divided into responders (decrease Lichtiger Score ≥50%) nonresponders. The microbiome was by the 16S rRNA gene marker analyzed QIIME 2. Microbial pathways predicted using parsimonious flux balance analysis. Results Among 93 included patients, 69 (74%) responded weeks. At baseline, could not be distinguished from nonresponders diversity composition, except a subgroup biologic-naïve patients. Within treatment, experienced changes beta enrichment ascribed beneficial taxa, including Blautia, Anaerostipes, Bifidobacterium, as well an increase butyrate synthesis. Nonresponders had only minor longitudinal taxonomic significant Streptococcus salivarius shifting away responders. Conclusion Baseline seem limited use predict Response is longitudinally restoration capacity.

Language: Английский

Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets DOI Creative Commons
Arno R. Bourgonje, Damian Klóska, Anna Grochot-Przęczek

et al.

Redox Biology, Journal Year: 2023, Volume and Issue: 60, P. 102603 - 102603

Published: Jan. 6, 2023

Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are intimately associated with inflammation overproduction of reactive oxygen species (ROS). Temporal inter-individual variabilities in activity response to therapy pose significant challenges diagnosis patient care. Discovery validation truly integrative biomarkers would benefit from embracing redox metabolomics approaches prioritization central regulatory hubs. We here make a case for applying personalized medicine approach that aims selectively inhibit pathological and/or altered expression specific enzymatic sources ROS without compromising physiological function. To this end, improved 'clinical-omics integration' may help better understand which particular signaling pathways disrupted what patient. Pharmacological interventions capable activating endogenous antioxidant defense systems represent viable therapeutic options restore local/systemic status, HIF-1α NRF2 holding promise context. Achieving the implementation clinically meaningful mechanism-based requires development easy-to-use, robust cost-effective tools secure monitoring treatment efficacy. Ultimately, matching redox-directed pharmacological individual phenotypes using predictive offer new opportunities break ceiling IBD.

Language: Английский

Citations

60
Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases DOI Open Access
Mohamed Kamel,

Sami Aleya,

Majed Alsubih

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(2), P. 217 - 217

Published: Feb. 18, 2024

Infectious diseases have long posed a significant threat to global health and require constant innovation in treatment approaches. However, recent groundbreaking research has shed light on previously overlooked player the pathogenesis of disease-the human microbiome. This review article addresses intricate relationship between microbiome infectious unravels its role as crucial mediator host-pathogen interactions. We explore remarkable potential harnessing this dynamic ecosystem develop innovative strategies that could revolutionize management diseases. By exploring latest advances emerging trends, aims provide new perspective combating by targeting

Language: Английский

Citations

23
Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease DOI
Defeng Li, Meifeng Yang, Haoming Xu

et al.

Journal of Materials Chemistry B, Journal Year: 2022, Volume and Issue: 10(31), P. 5853 - 5872

Published: Jan. 1, 2022

As a group of chronic and idiopathic gastrointestinal (GI) disorders, inflammatory bowel disease (IBD) is characterized by recurrent intestinal mucosal inflammation.

Language: Английский

Citations

56
Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer’s disease? DOI Creative Commons
Sophia Mirkin, Benedict C. Albensi

Frontiers in Aging Neuroscience, Journal Year: 2023, Volume and Issue: 15

Published: April 18, 2023

Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that affects memory, thinking, behavior, and other cognitive functions. Although there no cure, detecting AD early important for the development of therapeutic plan care may preserve function prevent irreversible damage. Neuroimaging, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission (PET), has served critical tool in establishing diagnostic indicators during preclinical stage. However, neuroimaging technology quickly advances, challenge analyzing interpreting vast amounts brain data. Given these limitations, great interest using artificial Intelligence (AI) to assist this process. AI introduces limitless possibilities future diagnosis AD, yet still resistance from healthcare community incorporate clinical setting. The goal review answer question whether should be used conjunction with AD. To question, possible benefits disadvantages are discussed. main advantages its potential improve accuracy, efficiency radiographic data, reduce physician burnout, advance precision medicine. include generalization data shortage, lack vivo gold standard, skepticism medical community, bias, concerns over patient information, privacy, safety. challenges present fundamental must addressed when time comes, it would unethical not use if can health outcome.

Language: Английский

Citations

26
Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease DOI
Marietta Iacucci, Giovanni Santacroce, Irene Zammarchi

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2024, Volume and Issue: 9(8), P. 758 - 772

Published: May 15, 2024

Language: Английский

Citations

15
Challenges in IBD Research 2024: Precision Medicine DOI Creative Commons
Sana Syed, Brigid S. Boland,

Lauren T Bourke

et al.

Inflammatory Bowel Diseases, Journal Year: 2024, Volume and Issue: 30(Supplement_2), P. S39 - S54

Published: May 1, 2024

Abstract Precision medicine is part of 5 focus areas the Challenges in IBD Research 2024 research document, which also includes preclinical human mechanisms, environmental triggers, novel technologies, and pragmatic clinical research. Building on 2019, current aims to provide a comprehensive overview gaps inflammatory bowel diseases (IBDs) deliver actionable approaches address them with how these can lead advancements interception, remission, restoration for diseases. The document result multidisciplinary input from scientists, clinicians, patients, funders, represents valuable resource patient-centric prioritization. In particular, precision section focused main elucidating bring best care individual patient IBD. were identified biomarker discovery validation predicting disease progression choosing most appropriate treatment each patient. Other making use existing biosamples data, developing new technologies analyze large datasets, overcoming regulatory payer hurdles enable biomarkers. To gaps, Workgroup suggests focusing thoroughly validating candidate biomarkers, using best-in-class data generation analysis tools, establishing cross-disciplinary teams tackle as early possible. Altogether, group recognizes importance bringing basic scientific translating it into clinic help improve lives patients.

Language: Английский

Citations

10
Biomarkers in inflammatory bowel disease: a practical guide DOI Creative Commons
Jennifer Clough,

M Colwill,

Andrew Poullis

et al.

Therapeutic Advances in Gastroenterology, Journal Year: 2024, Volume and Issue: 17

Published: Jan. 1, 2024

Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s (CD), is a costly condition in terms of morbidity healthcare utilization, with an increasing prevalence now approaching 1% the Western world. Endoscopic assessment IBD remains gold standard for diagnosis, evaluation treatment response determination post-operative recurrence, but expensive invasive. Biomarkers can facilitate non-invasive assessment, C-reactive protein faecal calprotectin as most widely available biomarkers current clinical practice. This narrative review summarizes evidence their use both UC CD offers practical guidance providers taking into account limitations biomarker interpretation. We present future novel discuss how discovery could deliver goal precision medicine IBD.

Language: Английский

Citations

9
Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease DOI Creative Commons
Yiran Zhang,

John P. Thomas,

Tamás Korcsmáros

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(9), P. 101738 - 101738

Published: Sept. 1, 2024

Language: Английский

Citations

8
Propionic Acid Driven by the Lactobacillus johnsonii Culture Supernatant Alleviates Colitis by Inhibiting M1 Macrophage Polarization by Modulating the MAPK Pathway in Mice DOI
Zhifeng Wu,

Jinhui He,

Zeyue Zhang

et al.

Journal of Agricultural and Food Chemistry, Journal Year: 2023, Volume and Issue: 71(41), P. 14951 - 14966

Published: Oct. 3, 2023

In this study, we investigated the effects of Lactobacillus johnsonii on mouse colitis model. The results showed that supernatant L. culture alleviated and remodeled gut microbiota, represented by an increased abundance bacteria producing short-chain fatty acids, leading to concentration propionic acid in intestine. Further studies revealed inhibited activation MAPK signaling pathway polarization M1 macrophages. Macrophage clearance assays confirmed macrophages are indispensable for alleviating through acid. vitro experiments directly reduced macrophage polarization, thereby inhibiting secretion pro-inflammatory cytokines. These findings improve our understanding how attenuates inflammatory bowel disease (IBD) provide valuable insights identifying molecular targets IBD treatment future.

Language: Английский

Citations

18
Precision medicine in inflammatory bowel disease DOI Creative Commons
Zhen Zeng, Mingshan Jiang, Xi Li

et al.

Precision Clinical Medicine, Journal Year: 2023, Volume and Issue: 6(4)

Published: Oct. 25, 2023

Abstract Inflammatory bowel disease (IBD) is an incurable characterized by remission-relapse cycles throughout its course. Both Crohn's (CD) and ulcerative colitis (UC), the two main forms of IBD, exhibit tendency to develop complications substantial heterogeneity in terms frequency severity relapse, thus posing great challenges clinical management for IBD. Current treatment strategies are effective different ways induction maintenance therapies Recent advances studies genetics, pharmacogenetics, proteomics microbiome provide a strong driving force identifying molecular markers prognosis response, which should help clinicians manage IBD patients more effectively, then, improve outcomes reduce costs patients. In this review, we summarize discuss precision medicine focusing on predictive course monitoring indices during therapeutic drug monitoring.

Language: Английский

Citations

15